AIM: Aberrant hepatic artery is particularly common, and its diversity and complexity play a critical role in surgery. The aim of this study was to describe the incidence and type of aberrant hepatic artery, and to compare differences in transarterial chemoembolization (TACE) in patients with hepatocellular carcinoma (HCC) with vs without aberrant hepatic artery. METHODS: This was a retrospective study of patients with HCC who received TACE at the same intervention center between March 15, 2020 and December 31, 2022. All patients who met inclusion criteria were divided into two groups based on whether or not they had aberrant hepatic artery. The aberrant hepatic artery was systematically classified according to variations in origin. We compared differences in baseline characteristics, operation duration, and postoperative hospitalization between the two groups. Postoperative adverse events and laboratory data were also compared. RESULTS: A total of 1250 patients hospitalized with HCC were included in the study (mean age, 58 ± 10 years, 1019 [81.5%] males). A high incidence of aberrant hepatic artery was found during TACE (21.3%, 266 of 1250), mainly involving a single variation of the aberrant left hepatic artery (aLHA) (6.1%, 76 of 1250) or aberrant right hepatic artery (aRHA) (10.9%, 136 of 1250) origin, as well as complex variations of the aLHA and aRHA origin (2.4%, 30 of 1250). When comparing patients with vs without aberrant hepatic artery, the TACE operation duration was significantly different (p < 0.001), and tended to be greater for patients with aberrant hepatic artery. In addition, differences between aberrant and normal hepatic artery groups in postoperative nausea and vomiting were statistically significant (40.2% vs 30.8%, respectively, p = 0.004). Postoperative laboratory examinations revealed significant differences in aspartate aminotransferase, alanine aminotransferase, and neutrophil percentage between the two groups (p < 0.05). CONCLUSIONS: The incidence of aberrant hepatic artery is extremely high, and the condition is characterized by complex variations. Moreover, aberrant hepatic artery may have a critical impact on the course of TACE treatment.

Background: The hepatic artery has several variations that can be observed by digital subtraction angiography (DSA). In recent years, clinical studies have continued to explore its diversity, leading to the discovery of rare variations and the development of new classifications. Methods: Institutional Review Board approval was attained. This retrospective study was based on analysis of DSA images in 1141 patients who were pathologically or clinically diagnosed with liver tumor from May 2015 to December 2019. All patients involved in this study had undergone hepatic arteriography at our hospital. The study aimed to complete angiographic assessments of the left gastric artery (LGA), superior mesenteric artery (SMA) and HA, which supply the liver parenchyma. Results: It was worth mentioning that we found five new cases of hepatic artery variations. The four major types of hepatic artery anatomy were identified. Normal hepatic artery anatomy was pointed in 871 (76.3%) of 1141 patients, and the incidence of hepatic artery variation was 270 (23.7%) cases. Variation in hepatic artery origin was identified in 240 (21.1%) cases. Variation in bifurcation was identified in 18 (1.6%) cases. Three (0.5%) cases had synchronized bifurcate and variation of origin, which has not been reported previously. Conclusion: Hepatic artery variation have diversity and complexity. The known and newly is covered variations were thoroughly analyzed in detail, which has important clinical significance for hepatobiliary surgeries and interventional operations.

Reprogrammed glucose metabolism is essential for tumor initiation and development, especially for pancreatic ductal adenocarcinoma (PDAC). Most cancer cells rely on aerobic glycolysis, a phenomenon termed "the Warburg effect", to support uncontrolled proliferation and evade apoptosis. However, the direct regulators of the Warburg effect remain areas of active investigation. In this study, we found that the highly conserved transcription factor, TWIST1, is a crucial regulator of aerobic glycolysis in PDAC. Genetic silencing of TWIST1 significantly inhibited the glycolytic phenotypes of PDAC cells as revealed by reduced glucose uptake, lactate production, and extracellular acidification rate, which can be restored by re-expression of siRNA-resistant TWIST1. Moreover, tamoxifen-inducible expression of TWIST1 promoted the Warburg metabolism of PDAC cells. Mechanistically, by luciferase reporter assay and chromatin immunoprecipitation experiment, we showed that TWIST1 can directly increase the expression of several glycolytic genes, including SLC2A1, HK2, ENO1, and PKM2. Of note, the transcriptional regulation by TWIST1 was not dependent on HIF1α or c-Myc. In The Cancer Genome Atlas and Gene Expression Omnibus accession GSE15471, we confirmed that TWIST1 was closely associated with the glycolysis pathway. Collectively, our findings indicate that TWIST1 is likely to act as important regulator of the Warburg effect in PDAC.

Cluster of differentiation (CD)133 is considered to be a marker of leukemia stem cells (LSCs), which are one of the primary causes of occurrence, drug resistance and relapse of acute lymphoblastic leukemia (ALL). CD82, an adhesion molecule, performs an important role in the interaction between LSCs and their niche. The purpose of the present study was to assess CD133 and CD82 expression in patients with pediatric ALL, and to evaluate the association with the clinical data. Using flow cytometric assessment and reverse transcription-polymerase chain reaction, CD133 and CD82 expression levels were measured in the bone marrow (BM) of 37 patients with newly diagnosed (ND) pediatric ALL [ALL-ND; 30 B-cell-ALL (B-ALL) and 7 T-cell-ALL (T-ALL)], in 22 patients with complete remission pediatric ALL (ALL-CR) and in 16 age-matched children without BM disease. BM plasma CD82 concentrations were measured by ELISA. The CD82 mRNA expression level in the patients with ALL-ND was significantly higher compared with that in the controls. CD82 mRNA expression levels in pediatric patients with B cell-ALL (B-ALL) were higher than those in ALL-CR patients and controls. For T-ALL, CD82 expression in ND patients was higher than in controls. CD133 mRNA expression levels in patients with pediatric B-ALL-ND were higher than that of controls and patients with ALL-CR. The frequency of CD34+ cells in pediatric ALL was significantly higher than that in controls. Frequencies of CD34+CD133+ or CD34+CD82+ cells in pediatric ALL were higher than those in controls. A positive association was observed between CD133 and CD82 mRNA expression in patients with B-ALL. A significant association was observed between CD133 mRNA expression and the hyperdiploid karyotype. Therefore, it was considered that CD133 and CD82 may serve an important role in the evolution of pediatric ALL. CD133 and CD82 should be considered as potential markers for the prognosis of patients with ALL.